Sertindole

CHEMBL12713 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
440.9 g/mol
LogP
4.1
Phase
4

Sertindole is an atypical antipsychotic of the phenylindole class with high affinity for dopamine D2, serotonin 5-HT2A, and alpha-1 adrenergic receptors, used for the treatment of schizophrenia and investigated in bipolar disorder and generalized anxiety disorder. Its unique receptor binding profile, with greater affinity for mesolimbic versus nigrostriatal dopamine pathways, provides antipsychotic efficacy with reduced extrapyramidal side effects. QTc prolongation risk limits its use and requires cardiac monitoring.

น้ำหนักโมเลกุล

440.9000 g/mol

LogP

4.10

TPSA

40.50 Ų

Lipinski RO5

ผ่าน

ด้านการรักษา

Pharmacokinetics (PK)

Pharmacodynamics (PD)

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1

InChI

InChI=1S/C24H26ClFN4O/c25-18-1-6-23-21(15-18)22(16-30(23)20-4-2-19(26)3-5-20)17-7-10-28(11-8-17)13-14-29-12-9-27-24(29)31/h1-6,15-17H,7-14H2,(H,27,31)

Molecular Formula

C24H26ClFN4O

HBD / HBA

1 / 3

พันธะที่หมุนได้

5

อะตอมหนัก

31

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

Sertindole is an atypical antipsychotic of the phenylindole class with high affinity for dopamine D2, serotonin 5-HT2A, and alpha-1 adrenergic receptors, used for the treatment of schizophrenia and investigated in bipolar disorder and generalized anxiety disorder. Its unique receptor binding profile, with greater affinity for mesolimbic versus nigrostriatal dopamine pathways, provides antipsychotic efficacy with reduced extrapyramidal side effects. QTc prolongation risk limits its use and requires cardiac monitoring.

Yes, Sertindole is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL12713. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 60149. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.